Physician profile
Jade Law
NPI 1952898884
$5,481.49
in general payments reported to CMS, 2019-2025
38 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,727 · 2023: $1,705 · 2024: $1,643 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.81 |
| Education | $264.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $559.20 | 2022-2025 | |
| Genzyme Corporation | $509.45 | 2022-2024 | |
| Incyte Corporation | $447.86 | 2022-2024 | Jakafi, Pemazyre, Monjuvi |
| Alexion Pharmaceuticals, INC. | $327.63 | 2022-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $315.91 | 2023-2025 | Calquence, Enhertu |
| Celgene Corporation | $286.19 | 2022-2024 | Reblozyl, Pomalyst |
| Secura Bio, INC. | $278.23 | 2022 | |
| Sobi, INC | $275.46 | 2022 | |
| Servier Pharmaceuticals LLC | $193.25 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $177.03 | 2023-2025 | Vyxeos, Zepzelca |
| Seagen INC. | $169.95 | 2023 | Adcetris, Tukysa |
| Aadi Bioscience, INC. | $158.73 | 2022-2024 | Fyarro |
| Amgen INC. | $155.26 | 2022-2023 | Blincyto, Kyprolis |
| Merck Sharp & Dohme LLC | $147.96 | 2022-2025 | Keytruda, Dificid, Prevymis |
| Rigel Pharmaceuticals, INC. | $129.12 | 2022-2024 | Tavalisse, Rezlidhia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $116.33 | 2023-2024 | Bavencio |
| Exelixis INC. | $107.65 | 2023-2024 | Cabometyx |
| Beigene USA, INC. | $101.02 | 2022-2024 | Brukinsa |
| Daiichi Sankyo INC. | $97.96 | 2023-2025 | Enhertu, Vanflyta |
| Blueprint Medicines Corporation | $95.90 | 2023-2024 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $93.54 | 2024-2025 | |
| Janssen Biotech, INC. | $92.05 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Ipsen Biopharmaceuticals, INC | $76.85 | 2022-2024 | Onivyde, Somatuline Depot |
| Takeda Pharmaceuticals U.S.A., INC. | $60.69 | 2022-2024 | Livtencity |
| Alnylam Pharmaceuticals INC. | $58.68 | 2022-2023 | Givlaari |
| Karyopharm Therapeutics INC. | $53.57 | 2024 | Xpovio |
| Adc Therapeutics America, INC. | $51.20 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $47.44 | 2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $40.07 | 2023-2025 | Qinlock, Tgct |
| Bayer Healthcare Pharmaceuticals INC. | $39.41 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $38.75 | 2024 | Libtayo |
| Pfizer INC. | $37.77 | 2024 | |
| Kite Pharma, INC. | $34.06 | 2024 | Yescarta |
| Puma Biotechnology, INC. | $27.95 | 2023 | |
| Tolmar, INC. | $25.22 | 2023 | |
| Genentech USA, INC. | $21.71 | 2023 | Phesgo |
| Immunocore Limited | $17.18 | 2024 | Kimmtrak |
| E.R. Squibb & Sons, L.L.C. | $15.26 | 2024 | Opdualag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.